New infusion strategy aims to keep CAR t cells fighting leukemia longer
NCT ID NCT03186118
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have already achieved remission with CAR T cells. The main goals are to check safety and see if the approach is feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- T-cell Antigen Presenting Cells expressing truncated CD19 (T-APCs)
- What this could lead to
- If it works, this could help CAR T cells stay active longer and reduce the chance of leukemia coming back after treatment.
- What could go wrong
- This is a very early, small pilot study (Phase 1) focused on safety and feasibility. It may not show clear benefit, and there are risks of side effects from the infusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD 19+ ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.